Categories: Health

Debiopharm Explores Potential Of Inhibitor Debio 0123 in Phase 1 Cancer Study

(adsbygoogle = window.adsbygoogle || []).push({});

LAUSANNE, Switzerland, Dec. 17, 2021 /PRNewswire/ — Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy in patients with advanced solid tumors (NCT05109975). Part of an emerging new class of drugs working within the DNA damage response (DDR) pathway, the compound’s anti-tumor capacity has been evaluated in several preclinical studies along with the ongoing phase I study in combination with carboplatin-based chemotherapy. This new trial’s primary objective is to identify the maximum tolerated dose and/or recommended phase II dose in adults with advanced solid tumors that have recurred or progressed after prior therapy and/or for whom no standard therapy of proven benefit is available.

The development of the Debio 0123 program is rooted in the growing understanding of the DNA damage response of cancer cells. Research reveals that cancer cell survival relies on the tightly regulated cell cycle that pauses at certain points to allow the repair of damaged DNA so that tumor cells can continue to divide and grow. WEE1 is a catalyzing enzyme implicated in these “DNA repair stops” helping cancer to thrive. By inhibiting WEE1, the cell cycle checkpoints are compromised, driving cancer cells to start their replicating prematurely, or before the repair of detrimental DNA damage, ultimately leading to cell death. Furthermore, WEE1 inhibitors are suspected to selectively target tumor cells, inducing synthetic lethality without impacting survival of normal cells. The potential best-in class status of Debio 0123 relies on its highly selective inhibition against WEE1.

“We’re intrigued to learn more about the clinical benefits that WEE1 inhibition with Debio 0123 alone could offer cancer patients. We believe that this new modality can effectively exploit the genomic instability and malfunctioning of the DNA repair process in cancer cells in hopes that ultimately tumor progression is halted and patient survival is improved,” Dr. Esteban Rodrigo Imedio, Senior Medical Director, Oncology Research & Development, Debiopharm. “As Debio 0123 is highly selective against WEE1, in time, ongoing clinical research could confirm Debio 0123’s potential best-in-class status.”

Initially discovered by Almac Discovery before being in-licensed by Debiopharm in 2017, the evaluation of Debio 0123 as monotherapy could help to better characterize the safety and efficacy profile of the compound in a clinical setting and define the parameters for eventual phase II research.  Pre-clinical research suggests potential activity for cancer patients, particularly in combination with DNA damaging agents such as chemo- and radiotherapy. WEE1 inhibitors are promising drug candidates as they inhibit DDR, offering the possibility to enhance the efficacy of these agents, frequently part of the standard-of-care of various cancer types. Debiopharm plans to advance the clinical program while simultaneously negotiating potential partnerships, such as during the upcoming JP Morgan 2022 conference, with larger pharmaceutical companies for eventual commercialization.

Dr. Stephen Barr, Managing Director & President, Almac Discovery commented“Since the discovery of our highly selective WEE1 inhibitor, now known as Debio 0123, we have looked forward with anticipation to understanding its potential therapeutic benefit for cancer patients across the globe. We are therefore delighted that, in addition to the ongoing combination clinical study, Debio 0123 is also being evaluated as a monotherapy in the treatment of advanced solid tumors. We look forward to seeing further progress from this ongoing clinical research.”

(adsbygoogle = window.adsbygoogle || []).push({});
(adsbygoogle = window.adsbygoogle || []).push({});

admin

Recent Posts

A Long Week In Politics For Anwar Ends Well

A massive divide between the races in the voting patterns that have left Anwar with…

3 days ago

Anwar Is Fighting Rising Prices With Targeted Subsidies

Nevertheless, Anwar has said he plans to introduce a programme that will include targeted subsidies…

1 week ago

APEC: China’s Return To The Global Supply Chains

The question to ask is whether there are one too many free trade agreements around…

2 weeks ago

RCEP Came At A Good Time

After the upsets with the South China Sea disputes, we now have certain normalcy, which…

2 weeks ago

US Popularity In The Asean region

In Vietnam, the sentiments can be different because they see the Chinese encroachments in the…

3 weeks ago

New Views On Asean Plus Three and China

Asean plus three is still important for the Asean but with China's dominance, so to…

3 weeks ago